2020
DOI: 10.1016/j.omtn.2020.07.027
|View full text |Cite
|
Sign up to set email alerts
|

circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway

Abstract: Gefitinib is a first-line treatment for patients with non-smallcell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated that circular RNAs play a crucial role in chemoresistance, but their expression and function in NSCLC cells with acquired resistance to gefitinib are largely unknown. In this study, we determined that circSETD3 was significantly upregulated in gefitinib-resistant NSC… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
14
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(16 citation statements)
references
References 49 publications
2
14
0
Order By: Relevance
“…In our study, we found circSETD3 played as a tumor suppressor in HB via regulating miR-423-3p/Bim axis. Previous studies have reported that circSETD3 exerts as an oncogene in nasopharyngeal carcinoma and non-small cell lung cancer, but acts as a tumor suppressor in hepatocellular carcinoma ( Xu et al, 2019 ; Huang et al, 2020 ; Tang et al, 2020 ). Our results supported the circSETD3 acts as a tumor suppressor in liver cancer.…”
Section: Discussionmentioning
confidence: 99%
“…In our study, we found circSETD3 played as a tumor suppressor in HB via regulating miR-423-3p/Bim axis. Previous studies have reported that circSETD3 exerts as an oncogene in nasopharyngeal carcinoma and non-small cell lung cancer, but acts as a tumor suppressor in hepatocellular carcinoma ( Xu et al, 2019 ; Huang et al, 2020 ; Tang et al, 2020 ). Our results supported the circSETD3 acts as a tumor suppressor in liver cancer.…”
Section: Discussionmentioning
confidence: 99%
“… 22 In addition, it was reported that the downregulation of serine/arginine splicing factor 1 (SRSF1) contributed to, at least in part, the increased expression of circSETD3 in NSCLC cells with acquired resistance to gefitinib in NSCLC. 23 Research has confirmed that the present research performed a circRNA microarray analysis for the expression profile and identified a novel circRNA (circMAGI3, hsa_circ_0110498). Clinically, circMAGI3 was significantly up-regulated in NSCLC tissue and cells, which was closely correlated with an unfavorable outcome for NSCLC patients.…”
Section: Discussionsupporting
confidence: 79%
“…The EGFR tyrosine kinase inhibitors (TKI) have been used selectively for decades to treat patients of NSCLC activated by EGFR mutations. 5 Advantages of EGFR-TKIs are improved prognosis and progression free survival of NSCLC patients as compared to the cytotoxic moieties ( Huang et al, 2020 , Xie et al, 2020 ). Typically, it was observed that EGFR mutations occurs in approximately 50% of the Asian patients and 10% of the white patients with NSCLC.…”
Section: Introductionmentioning
confidence: 99%